Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance

Trends in Pharmacological Sciences

Volumn 38, Issue 7, 2017, Pages 649-665

  Petersen, Max C ^a   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ceramide; ectopic lipid; insulin receptor kinase; insulin resistance; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; protein kinase C epsilon

Indexed keywords

2,4 DINITROPHENOL; ARACHIDONIC ACID; CERAMIDE; DECANOIC ACID; DEXAMETHASONE; DIACYLGLYCEROL; DOCOSAHEXAENOIC ACID; ESTRADIOL; FENRETINIDE; FIBROBLAST GROWTH FACTOR 21; INSULIN; LINOLEIC ACID; NICLOSAMIDE; PENTADECANOIC ACID; SALICYLIC ACID; THERMOZYMOCIDIN; TRIACYLGLYCEROL LIPASE;

BODY MASS; DISEASE ASSOCIATION; HEPATIC INSULIN RESISTANCE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER DISEASE; MEDIATOR RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; NONALCOHOLIC FATTY LIVER;

ANIMALS; CERAMIDES; DIGLYCERIDES; HUMANS; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85019649050     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.04.004     Document Type: Review

References (128)

1. World Health Organization, Global Report on Diabetes., 2016, World Health Organization.
2. 13C nuclear magnetic resonance study. J. Clin. Invest. 90 (1992), 1323–1327.
3. Basu, R., et al. Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 54 (2005), 1942–1948.
4. Perry, R.J., et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160 (2015), 745–758.
5. Boden, G., et al. Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 280 (2001), E23–E30.
6. Krssak, M., et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53 (2004), 3048–3056.
7. Hundal, R.S., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49 (2000), 2063–2069.
8. Petersen, K.F., et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54 (2005), 603–608.
9. Leite, N.C., et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 29 (2009), 113–119.
10. Targher, G., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007), 1212–1218.
11. Silverman, J.F., et al. Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenterol. 85 (1990), 1349–1355.
12. Marchesini, G., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107 (1999), 450–455.
13. Bugianesi, E., et al. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005), 987–1000.
14. Korenblat, K.M., et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134 (2008), 1369–1375.
15. Tiikkainen, M., et al. Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes. Res. 10 (2002), 859–867.
16. Fabbrini, E., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 15430–15435.
17. Magkos, F., et al. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 18 (2010), 1510–1515.
18. Yamazaki, H., et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 38 (2015), 1673–1679.
19. Lotta, L.A., et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat. Genet. 49 (2017), 17–26.
20. Samuel, V.T., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279 (2004), 32345–32353.
21. Hebbard, L., George, J., Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8 (2011), 35–44.
22. Petersen, K.F., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109 (2002), 1345–1350.
23. Perry, R.J., et al. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347 (2015), 1253–1256.
24. Perry, R.J., et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab. 18 (2013), 740–748.
25. Kim, J.K., et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275 (2000), 8456–8460.
26. Tao, H., et al. Niclosamide ethanolamine improves blood glycemic control and reduces hepatic steatosis in mice. Nat. Med. 20 (2014), 1263–1269.
27. Takayama, S., et al. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J. Biol. Chem. 263 (1988), 3440–3447.
28. Takayama, S., et al. Phorbol esters modulate insulin receptor phosphorylation and insulin action in cultured hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 81 (1984), 7797–7801.
29. Turinsky, J., et al. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J. Biol. Chem. 265 (1990), 16880–16885.
30. Shmueli, E., et al. Diacylglycerol/protein kinase C signalling: a mechanism for insulin resistance?. J. Intern. Med. 234 (1993), 397–400.
31. Kumashiro, N., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16381–16385.
32. Perry, R.J., et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510 (2014), 84–91.
33. Camporez, J.P.G., et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154 (2013), 3099–3109.
34. Camporez, J.P.G., et al. ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. J. Lipid Res. 56 (2015), 526–536.
35. Magkos, F., et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142 (2012), 1444–1446.e2.
36. Jornayvaz, F.R., Shulman, G.I., Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab. 15 (2012), 574–584.
37. Luukkonen, P.K., et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64 (2016), 1167–1175.
38. ter Horst, K.W., et al. Hepatic diacylglycerol-associated protein kinase Cε translocation links hepatic steatosis to hepatic insulin resistance in humans. Cell Rep., 2017 (in press).
39. Camporez, J.P.G., et al. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology 154 (2013), 1021–1028.
40. Abulizi, A., et al. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice. FASEB J., 2017, 10.1096/fj.201700001R Published online March 22, 2017.
41. Savage, D.B., et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116 (2006), 817–824.
42. Birkenfeld, A.L., et al. Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metab. 14 (2011), 184–195.
43. Erion, D.M., et al. Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab. 10 (2009), 499–506.
44. Samuel, V.T., et al. Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Invest. 117 (2007), 739–745.
45. Raddatz, K., et al. Time-dependent effects of Prkce deletion on glucose homeostasis and hepatic lipid metabolism on dietary lipid oversupply in mice. Diabetologia 54 (2011), 1447–1456.
46. Petersen, M.C., et al. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J. Clin. Invest. 126 (2016), 4361–4371.
47. Neschen, S., et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab. 2 (2005), 55–65.
48. Nagle, C.A., et al. Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance. J. Biol. Chem. 282 (2007), 14807–14815.
49. Ryu, D., et al. Endoplasmic reticulum stress promotes LIPIN2-dependent hepatic insulin resistance. Diabetes 60 (2011), 1072–1081.
50. Ryu, D., et al. TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab. 9 (2009), 240–251.
51. Choi, C.S., et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J. Biol. Chem. 282 (2007), 22678–22688.
52. Monetti, M., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6 (2007), 69–78.
53. Jornayvaz, F.R., et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 5748–5752.
54. Finck, B.N., Hall, A.M., Does diacylglycerol accumulation in fatty liver disease cause hepatic insulin resistance?. Biomed. Res. Int., 2015, 2015, 104132.
55. Kamiya, Y., et al. Activation of conventional and novel protein kinase C isozymes by different diacylglycerol molecular species. Biochem. Biophys. Rep. 7 (2016), 361–366.
56. Shirai, Y., et al. Distinct effects of fatty acids on translocation of gamma- and epsilon-subspecies of protein kinase C. J. Cell Biol. 143 (1998), 511–521.
57. Brown, J.M., et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J. Lipid Res. 51 (2010), 3306–3315.
58. Cantley, J.L., et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 1869–1874.
59. Minehira, K., et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J. Lipid Res. 49 (2008), 2038–2044.
60. Hall, A.M., et al. Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice. Diabetes 63 (2014), 2284–2296.
61. Fullerton, M.D., et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19 (2013), 1649–1654.
62. Xia, J.Y., et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 22 (2015), 266–278.
63. Peterson, T.A., Stamnes, M., ARF1-regulated coatomer directs the steady-state localization of protein kinase C epsilon at the Golgi apparatus. Biochim. Biophys. Acta 1833 (2013), 487–493.
64. Eichmann, T.O., et al. Studies on the substrate and stereo/regioselectivity of adipose triglyceride lipase, hormone-sensitive lipase, and diacylglycerol-O-acyltransferases. J. Biol. Chem. 287 (2012), 41446–41457.
65. Rando, R.R., Young, N., The stereospecific activation of protein kinase C. Biochem. Biophys. Res. Commun. 122 (1984), 818–823.
66. Petersen, M.C., Jurczak, M.J., CrossTalk opposing view: intramyocellular ceramide accumulation does not modulate insulin resistance. J. Physiol. 594 (2016), 3171–3174.
67. Summers, S.A., Goodpaster, B.H., CrossTalk proposal: intramyocellular ceramide accumulation does modulate insulin resistance. J. Physiol. 594 (2016), 3167–3170.
68. Schmitz-Peiffer, C., et al., Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J. Biol. Chem. 274 (1999), 24202–24210.
69. Turpin, S.M., et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20 (2014), 678–686.
70. Raichur, S., et al. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20 (2014), 687–695.
71. Hla, T., Kolesnick, R., C16:0-ceramide signals insulin resistance. Cell Metab. 20 (2014), 703–705.
72. Turner, N., et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 56 (2013), 1638–1648.
73. Montgomery, M.K., et al. Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding. Diabetologia 56 (2013), 1129–1139.
74. Montgomery, M.K., et al. Regulation of glucose homeostasis and insulin action by ceramide acyl-chain length: a beneficial role for very long-chain sphingolipid species. Biochim. Biophys. Acta 1861 (2016), 1828–1839.
75. Ussher, J.R., et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 59 (2010), 2453–2464.
76. Galbo, T., et al. Saturated and unsaturated fat induce hepatic insulin resistance independently of TLR-4 signaling and ceramide synthesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 12780–12785.
77. Holland, W.L., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5 (2007), 167–179.
78. Lee, H.-Y., et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 54 (2011), 1650–1660.
79. Trevino, M.B., et al. Liver perilipin 5 expression worsens hepatosteatosis but not insulin resistance in high fat-fed mice. Mol. Endocrinol. 29 (2015), 1414–1425.
80. Kurek, K., et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int. 34 (2014), 1074–1083.
81. Bikman, B.T., et al. Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis. J. Biol. Chem. 287 (2012), 17426–17437.
82. Holland, W.L., et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J. Clin. Invest. 121 (2011), 1858–1870.
83. Yang, Q., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 (2005), 356–362.
84. Kim, J.K., et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108 (2001), 437–446.
85. Holland, W.L., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17 (2011), 55–63.
86. Chavez, J.A., Summers, S.A., A ceramide-centric view of insulin resistance. Cell Metab. 15 (2012), 585–594.
87. Yang, G., et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E211–E224.
88. Salinas, M., et al. Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol. Cell. Neurosci. 15 (2000), 156–169.
89. Schubert, K.M., et al. Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473. J. Biol. Chem. 275 (2000), 13330–13335.
90. Zhou, H., et al. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol. Chem. 273 (1998), 16568–16575.
91. Stratford, S., et al. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279 (2004), 36608–36615.
92. Galbo, T., et al. PP2A inhibition results in hepatic insulin resistance despite Akt2 activation. Aging (Milano) 5 (2013), 770–781.
93. Caro, J.F., et al. Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J. Clin. Invest. 78 (1986), 249–258.
94. Watarai, T., et al. Alteration of insulin-receptor kinase activity by high-fat feeding. Diabetes 37 (1988), 1397–1404.
95. Henao-Mejia, J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
96. Vandanmagsar, B., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17 (2011), 179–188.
97. Holland, W.L., et al. Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol. Metab. 6 (2017), 267–275.
98. Fedak, K.M., et al. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg. Themes Epidemiol., 12, 2015, 14.
99. Peverill, W., et al. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int. J. Mol. Sci. 15 (2014), 8591–8638.
100. Farese, R.V. Jr, et al. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 15 (2012), 570–573.
101. Aburasayn, H., et al. Targeting ceramide metabolism in obesity. Am. J. Physiol. Endocrinol. Metab. 311 (2016), E423–E435.
102. Ader, M., Bergman, R.N., Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am. J. Physiol. 258 (1990), E1020–E1032.
103. Cherrington, A.D., The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia 41 (1998), 987–996.
104. Edgerton, D.S., et al. Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion. JCI Insight, 2, 2017, e91863.
105. Shulman, G.I., Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371 (2014), 1131–1141.
106. Centers For Disease Control, 2014 Diabetes Report Card., 2014, Centers For Disease Control.
107. Zhang, D., et al. Mitochondrial dysfunction due to long-chain acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 17075–17080.
108. Zhang, D., et al. Resistance to high-fat diet-induced obesity and insulin resistance in mice with very long-chain acyl-CoA dehydrogenase deficiency. Cell Metab. 11 (2010), 402–411.
109. Hoy, A.J., et al. Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin resistance despite reduced energy expenditure and ectopic lipid accumulation. Endocrinology 152 (2011), 48–58.
110. Turpin, S.M., et al. Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia 54 (2011), 146–156.
111. Kumashiro, N., et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology 57 (2013), 1763–1772.
112. Soufi, N., et al. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. J. Biol. Chem. 289 (2014), 30177–30188.
113. Samuel, V.T., et al. Targeting Foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55 (2006), 2042–2050.
114. Choi, C.S., et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 16480–16485.
115. Matsuzaka, T., et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat. Med. 13 (2007), 1193–1202.
116. Jaworski, K., et al. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat. Med. 15 (2009), 159–168.
117. Jornayvaz, F.R., et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am. J. Physiol. Endocrinol. Metab. 299 (2010), E808–E815.
118. Jornayvaz, F.R., et al. Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology 153 (2012), 583–591.
119. Jurczak, M.J., et al. Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. J. Biol. Chem. 287 (2012), 2558–2567.
120. Brown, W.H., et al. Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 14966–14971.
121. Sun, Z., et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 18 (2012), 934–942.
122. Zhu, L., et al. Estrogen signaling prevents diet-induced hepatic insulin resistance in male mice with obesity. Am. J. Physiol. Endocrinol. Metab. 306 (2014), E1188–E1197.
123. Chan, S.M.H., et al. Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice. Biochim. Biophys. Acta 1852 (2015), 1511–1519.
124. Jordy, A.B., et al. Analysis of the liver lipidome reveals insights into the protective effect of exercise on high-fat diet-induced hepatosteatosis in mice. Am. J. Physiol. Endocrinol. Metab. 308 (2015), E778–E791.
125. Aroor, A.R., et al. Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 64 (2015), 1988–2001.
126. Shang, J., et al. Duodenal–jejunal bypass surgery induces hepatic lipidomic alterations associated with ameliorated hepatic steatosis in mice. Obesity (Silver Spring) 24 (2016), 1938–1945.
127. Wilson, C.G., et al. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology 157 (2016), 570–585.
128. Popov, V.B., et al. Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance. FASEB J. 30 (2016), 1207–1217.